Monoclonal antibody | |
---|---|
Type | ? |
Clinical data | |
Other names | AE12-1Y-QL; ABT-555 |
Legal status | |
Legal status |
|
Identifiers | |
CAS Number | |
UNII |
Elezanumab (development names AE12-1Y-QL and ABT-555) is a fully human monoclonal antibody developed by AbbVie against repulsive guidance molecule A (RGMa). It has been tested in people with multiple sclerosis and acute ischemic stroke.[1][2][3][4]